logo
Takeda’sZasocitinibLandmarkPhase3PlaquePsoriasisDataShowPromisetoDeliverClearSkininaOnce-DailyPill,CatalyzingaNewEraofTreatment
===2025/12/19 9:50:40===
results in skin cells that multiply too quickly.7Plaque psoriasis, the most common form of psoriasis, is characterized by raised, red, gray or purple patches of skin that are itchy, painful and covered by scales.8-10Psoriatic plaques can cover any part of the skin surface but are mostly found on the scalp, face, arms and elbows, legs, knees, torso, genitals, nails and in skin folds.7,11Many people living with psoriasis experience intense itching and burning from their psoriasis plaques that disrupt their daily lives.9,10Patients also report that their symptoms negatively impact their mental health and quality of life and can lead to social isolation.12Globally, an estimated 64 million people are living with psoriasis and about 80-90% of those have plaque psoriasis.13,14

About Zasocitinib (TAK-279)

Zasocitinib is an investigational, next-generation, highly selective oral TYK2 inhibitor that maintains 24-hour inhibition of IL-23 plus other core disease-driving immune
=*=*=*=*=*=
当前为第5/20页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页